The global cancer biologics market size, valued at USD 189 billion in 2025, is projected to reach USD 210 billion in 2026 and USD 442 billion by 2035, with a CAGR of 8.6% during the forecast period 2026 to 2035. In the past few years, drug-based interventions (including biologics and small molecules) have observed a rapidly expanding pipeline for various types of cancer. The increased focus on personalized cancer biologics therapy market has garnered the interest of several pharmaceutical compan...

he broader focus will be on the development of tailored therapeutic drugs, including gene therapies, companion animal vaccines and recombinant proteins that can address animal’s unique needs.For instance, in February 2025, Bharat Biotech (India) announced that its Biolumpivaxin (vaccine for lumpy skin disease) has received the Central Drug Standards Control Organization license for cattle’s and buffaloes. As more market players continue to develop advanced biologics, it is expected that vete...

The global subcutaneous biologics market, valued at USD 250.6 billion in 2025, is projected to reach USD 267.6 billion in 2026 and USD 233.0 billion by 2035, during the forecast period 2026 to 2035. In the first quarter of 2024, nine biologics received the USFDA approval. This paradigm shift observed towards the preference of biologics can be attributed to their ability to offer targeted treatment (with minimal drug interactions) due to their specific binding and metabolic pathways. The exhausti...

The global biologics market size is worth around $411 billion in 2024 and is expected to reach $962 billion by 2035, representing a higher compounded annual growth rate (CAGR) of 8.04% during the forecast period. According to the World Health Organization report, nearly 422 million people across the globe are suffering from diabetes. Moreover, nearly 41 million people die annually due to non-communicable diseases, which is equivalent to around 74% of all deaths occurring across the globe. The ri...

The global retinal biologics market size is currently valued at $ 25.65 billion and is poised to reach $ 57.47 billion by 2035, it is estimated to grow at a CAGR of 7.61%, during the forecast period. There has been a surge in the number of patients suffering from various retinal diseases, such as diabetic retinopathy, glaucomatous retinal degeneration and age-related macular degeneration. As per the World Health Organization, in 2023, nearly 2.2 billion people have near, or distance vision impai...

The blockbuster drugs market was worth around $75 billion in 2020. Less than half a century ago, the pharmaceutical market was dominated by small molecule drugs. Notably, the first biologic, humanized insulin, was approved in 1982; over time, this class of target specific therapeutics have revolutionized the healthcare industry. Presently, biologics represent the fastest growing product segment within the global pharmaceutical industry. In fact, as of September 2020, over 430 biological interven...